Despite the fact that it has been three years since the drug was approved by the FDA, many oncologists still need to be educated regarding Xofigo's benefits beyond pain palliation, The ...

Brits in search of Bayer’s prostate cancer drug Xofigo or Sanofi’s colorectal drug Zaltrap should prepare for disappointment: the National Institute for Health and Care Excellence has said neither of ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

Oslo, Norway, 15 November 2013 - Algeta ASA (OSE: ALGETA) announces today that Bayer has received marketing authorisation from the European Commission for Xofigo ® (radium Ra 223 dichloride) solution ...

XOFIGO ® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate ...

Xofigo's role in the treatment of metastatic castration-resistant prostate cancer will continue to change. Xofigo (radium-223 dichloride), a radiopharmaceutical, is an efficacious bone-targeted agent ...

US-based Bayer Healthcare Pharmaceuticals, as its executives were quick to point out, has now received three new approvals for cancer indications in the last eight months US-based Bayer Healthcare ...

Bayer thought it might be able to expand Xofigo in prostate cancer by testing it with Johnson & Johnson’s Zytiga. But that plan has hit a snag. The German drugmaker unblinded a phase 3 study combining ...

Bayer’s cancer drug Xofigo is already a revenue driver for manufacturer Bayer. The company announced that the drug, approved for castration-resistant metastatic prostate cancer, earned $57 million ...

The HealthCare segment at Bayer ( BAYRY) received encouraging news when the European Commission (EC) cleared its oncology drug, Xofigo. Xofigo was approved in the EU for treating adults suffering from ...